New drug ORB-021 enters human testing for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests whether the investigational drug ORB-021 is safe and tolerable in 36 adults with advanced solid tumors that have not responded to standard treatments. Researchers will also find the best dose for future studies. Participants will go through screening,…
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated May 04, 2026 16:30 UTC